Hayek Kallen Investment Management acquired a new position in shares of Amarin Co. plc (NASDAQ:AMRN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 34,861 shares of the biopharmaceutical company’s stock, valued at approximately $528,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mcclain Value Management LLC boosted its holdings in shares of Amarin by 2.5% during the 2nd quarter. Mcclain Value Management LLC now owns 23,431 shares of the biopharmaceutical company’s stock worth $454,000 after buying an additional 577 shares during the period. Cambridge Investment Research Advisors Inc. increased its position in Amarin by 3.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 22,357 shares of the biopharmaceutical company’s stock valued at $434,000 after acquiring an additional 775 shares during the period. West Chester Capital Advisors Inc. increased its position in Amarin by 1.4% in the 2nd quarter. West Chester Capital Advisors Inc. now owns 60,607 shares of the biopharmaceutical company’s stock valued at $1,175,000 after acquiring an additional 815 shares during the period. US Bancorp DE increased its position in Amarin by 16.0% in the 2nd quarter. US Bancorp DE now owns 6,229 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 858 shares during the period. Finally, Glen Harbor Capital Management LLC increased its position in Amarin by 4.0% in the 2nd quarter. Glen Harbor Capital Management LLC now owns 22,616 shares of the biopharmaceutical company’s stock valued at $439,000 after acquiring an additional 880 shares during the period. 45.79% of the stock is owned by institutional investors.

In other news, Director Lars Ekman sold 91,016 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $15.01, for a total value of $1,366,150.16. Following the completion of the sale, the director now owns 13,500 shares in the company, valued at $202,635. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.75% of the company’s stock.

Shares of NASDAQ:AMRN traded up $0.72 during trading on Friday, reaching $17.48. The stock had a trading volume of 8,065,300 shares, compared to its average volume of 7,509,962. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.76 and a current ratio of 2.01. The firm’s fifty day moving average is $15.89 and its 200 day moving average is $17.35. Amarin Co. plc has a 52 week low of $11.78 and a 52 week high of $23.91. The stock has a market cap of $6.19 billion, a price-to-earnings ratio of -44.82 and a beta of 1.14.

Amarin (NASDAQ:AMRN) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. The company had revenue of $112.40 million during the quarter, compared to the consensus estimate of $110.04 million. Amarin had a negative net margin of 17.42% and a negative return on equity of 50.47%. The firm’s revenue for the quarter was up 104.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.08) earnings per share. On average, research analysts forecast that Amarin Co. plc will post -0.2 earnings per share for the current fiscal year.

Several equities analysts have issued reports on the stock. Leerink Swann set a $26.00 price target on shares of Amarin and gave the company a “buy” rating in a research report on Tuesday, September 10th. Stifel Nicolaus restated a “buy” rating and issued a $26.00 price target on shares of Amarin in a research report on Wednesday, July 31st. Svb Leerink assumed coverage on shares of Amarin in a research report on Wednesday, August 14th. They issued an “outperform” rating and a $26.00 price target for the company. BidaskClub upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Finally, HC Wainwright restated a “buy” rating on shares of Amarin in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $27.73.

Amarin Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Read More: Asset Allocation

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.